Expert’s summary: Abiraterone acetate, a small molecule inhibitor of cytochrome P17 (CYP17), inhibits 17 alpha-hydroxylase and C17, 20 lyase, both key enzymes in androgen synthesis. It was tested in 21 chemotherapy-naı̈ve men with metastatic prostate cancer that was resistant to multiple hormone therapies. Once-daily oral abiraterone acetatewas given at doses of 250 mg, 500 mg, 750 mg, 1000 mg, ...

Background Abiraterone acetate is an androgen synthesis inhibitor approved for the treatment of castration-resistant prostate cancer (CRPC). Although co-administration of either prednisone or prednisolone at 10 mg/d has been recommended to reduce the risk of abiraterone-induced hyperaldosteronism (notably hypokalemia) and to give adjunctive pain relief effects, whether these glucocorticoids can...

On December 10, 2012, the FDA approved the use of abiraterone acetate in patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC) prior to the use of chemotherapy (CT). The EMA, after a positive preliminary comment, approved on December 21, 2012, the use of abiraterone in the same case. This molecule has approved indication in CRPC, both post-CT and pre-CT...

Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for risk classification, although its utility for the chemotherapy-naive group is unclear. This study...

I n essentially just 1 year’s time, we have seen science translated into exciting new therapeutic agents for men with metastatic castration-resistant prostate cancer (CRPC), most recently with the United States Food and Drug Administration (FDA) approval of abiraterone acetate in combination with prednisone. While prostate cancer has been known to be highly responsive to surgical or medical cas...

Prostate cancer has long since been recognised as being hormonally driven via androgen receptor signalling. Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. AA has recently been proved to extend survival for men with metastatic castration-resistant...

I read with great interest the article by Auchus et al. [1] in which they comprehensively reviewed the use of prednisone with abiraterone acetate in the treatment of metastatic castrationresistant prostate cancer (CRPC). Although prednisolone is the most commonly used corticosteroid with abiraterone in clinical trials and is the standard of care as recommended by current guidelines, two recent ...

Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable oncological outcomes. Here, we aimed to compare the efficacy of novel AR-targeted agents by perf...